object
fever
common
adapt
immun
respons
acut
respiratori
tract
disord
infanc
antipyret
analges
drug
paracetamol
acetaminophen
wide
use
improv
comfort
child
may
caus
medic
unneed
antipyresi
rare
potenti
seriou
side
effect
assess
whether
treatment
pelargonium
sidoid
extract
ep
reduc
administr
paracetamol
children
acut
tonsillopharyng
atp
acut
bronchiti
ab
design
metaanalysi
randomis
placebocontrol
clinic
trial
method
search
clinic
trial
registri
isrctn
clinicaltrialsgov
medic
literatur
medlin
embas
randomis
placebocontrol
trial
investig
administr
ep
children
atp
ab
report
coadministr
paracetamol
base
individu
particip
data
elig
trial
studi
popul
character
accord
sex
age
metaanalys
perform
cumul
paracetamol
use
abil
attend
school
treatment
end
result
six
trial
includ
total
children
age
year
ep
placebo
suffer
streptococc
atp
trial
ab
trial
identifi
elig
children
receiv
ep
placebo
atp
day
ab
compar
placebo
ep
reduc
cumul
dose
paracetamol
trial
averag
mg
hedg
g
confid
interv
p
treatment
end
ep
placebo
children
still
unabl
attend
school
risk
ratio
confid
interv
p
conclus
children
age
year
ab
atp
ep
allevi
symptom
burden
acceler
recoveri
although
ep
known
antipyret
effect
concomit
use
paracetamol
reduc
fever
among
common
symptom
children
consult
paediatrician
estim
account
one
third
present
condit
although
regul
increas
bodi
temperatur
metabol
costli
organ
fever
shape
conserv
million
year
natur
select
confer
surviv
benefit
cope
inflamm
infect
outweigh
metabol
cost
immunolog
perspect
fever
adapt
host
respons
direct
antimicrobi
effect
augment
humor
cellular
defenc
mechan
vitro
experi
show
fever
play
key
role
reduc
virul
increas
clearanc
microorgan
well
stimul
immun
respons
support
activ
prolifer
lymphocyt
enhanc
phagocyt
potenti
dendrit
cell
augment
product
respons
viral
infect
evid
antipyresi
reduc
durat
diseas
children
fever
increas
risk
advers
outcom
studi
indic
overwhelmingli
use
antipyret
drug
may
prolong
ill
may
advers
affect
clinic
outcom
infect
may
even
increas
mortal
critic
ill
patient
moreov
administr
antipyret
drug
may
mask
import
clinic
sign
patient
condit
western
countri
administr
overthecount
otc
antipyret
drug
common
particularli
paediatr
set
parent
observ
administ
antipyret
even
case
minim
fever
mani
one
half
parent
found
administ
incorrect
dose
give
children
dose
supratherapeut
rang
contribut
factor
antipyret
overus
children
still
widespread
misconcept
parent
fever
diseas
rather
symptom
sign
ill
fever
associ
discomfort
fatigu
administr
antipyret
drug
mainli
motiv
desir
improv
overal
comfort
febril
child
belief
feel
better
direct
result
lower
fever
import
note
howev
drug
commonli
use
antipyresi
paracetamol
acetaminophen
acetylsalicyl
acid
ibuprofen
antipyret
also
analges
effect
benefici
effect
child
wellb
shown
mainli
attribut
analges
rather
antipyret
action
acut
respiratori
tract
infect
rti
among
common
caus
fever
children
estim
least
rti
viral
aetiolog
acut
tonsillopharyng
atp
highli
preval
season
infect
disord
character
inflamm
pharynx
palatin
tonsil
occur
age
group
account
visit
paediatr
care
common
symptom
atp
includ
sore
throat
dysphagia
red
pharynx
enlarg
tonsil
cover
yellow
bloodting
exud
fever
sudden
onset
malais
gastrointestin
complaint
halitosi
rhinorrhoea
cough
case
atp
viral
origin
rhinoviru
coronaviru
adenoviru
common
caus
epstein
barr
viru
influenza
parainfluenza
viru
may
also
caus
atp
bacteri
atp
commonli
caus
group
streptococcu
ga
whose
preval
children
age
atp
estim
lower
preval
preschool
children
anoth
common
rti
children
adult
acut
bronchiti
ab
condit
whose
primari
symptom
cough
typic
persist
week
sinc
cough
also
highli
preval
diseas
allerg
rhiniti
asthma
sinus
common
cold
differenti
diagnosi
may
demand
case
ab
assum
viral
origin
acut
viral
diseas
like
atp
ab
minim
treatment
emerg
risk
side
effect
justifi
notabl
children
unless
evid
bacteri
infect
antibiot
treatment
could
indic
focu
treatment
therefor
symptom
control
acceler
recoveri
atp
current
diseas
manag
guidelin
europ
north
america
agre
antibiot
treatment
administ
case
confirm
bacteri
infect
even
guidelin
advoc
use
antibiot
patient
increas
risk
sever
complic
support
treatment
recommend
case
aim
reliev
symptom
caus
atp
includ
analgesia
hydrat
rest
ab
inappropri
use
antibiot
infect
viral
origin
equal
discourag
instead
use
antituss
medic
e
g
dextromethorphan
codein
hydrocodon
suggest
dextromethorphan
particular
howev
shown
inefficaci
children
ab
treatment
associ
risk
prompt
american
academi
paediatr
food
drug
administr
fda
recommend
use
antituss
drug
children
year
age
expector
benefici
effect
could
demonstr
ab
well
ep
extract
root
pelargonium
sidoid
acut
respiratori
infect
atp
ab
randomis
placebocontrol
trial
confirm
symptom
allevi
effect
ep
comprehens
safeti
review
base
patient
expos
ep
show
advers
event
rate
similar
observ
placebo
pharmacolog
studi
indic
clinic
effect
ep
close
relat
antivir
antibacteri
action
extract
support
immun
respons
organ
stimul
releas
tumour
necrosi
factor
nitric
oxid
well
increas
activ
natur
killer
cell
although
ep
direct
virucid
effect
antivir
activ
achiev
reduct
host
cell
infect
attribut
inhibit
viru
replic
shown
season
influenza
viru
respiratori
syncyti
viru
human
coronaviru
parainfluenza
viru
coxsacki
viru
vitro
anim
model
moreov
ep
found
exert
antibacteri
effect
inhibit
adhes
ga
human
epitheli
cell
paracetamol
wide
use
medicin
product
children
long
recogn
safe
efficaci
analges
antipyret
drug
use
recommend
dose
rang
may
howev
caus
inept
antipyresi
potenti
seriou
advers
effect
paper
present
result
metaanalysi
randomis
placebocontrol
trial
perform
investig
whether
treatment
ep
may
reduc
coadministr
paracetamol
children
suffer
atp
ab
metaanalysi
clinic
trial
perform
assess
effect
ep
paracetamol
administr
children
suffer
atp
ab
ep
extract
root
pelargonium
sidoid
drugextract
ratio
extract
solvent
ethanol
ww
market
medicin
product
avail
liquid
solut
recommend
daili
dose
drop
young
children
age
year
drop
children
age
year
drop
adolesc
year
adult
filmcoat
tablet
contain
mg
extract
recommend
daili
dose
tablet
licens
adolesc
year
adult
syrup
formul
children
age
year
also
avail
use
identifi
studi
analysi
perform
use
individu
particip
data
doubleblind
randomis
placebocontrol
clinic
trial
ep
includ
children
year
age
one
target
indic
elig
studi
allow
concomit
use
paracetamol
report
amount
drug
administ
restrict
appli
studi
select
method
analysi
specifi
advanc
document
accordingli
studi
identifi
clinic
trial
registri
isrctn
clintrialsgov
medic
literatur
medlin
embas
search
earliest
record
end
decemb
use
term
ep
umckaloabo
combin
tonsillopharyng
sore
throat
acut
bronchiti
cough
well
placebo
control
titl
abstract
keyword
search
identifi
studi
examin
complianc
remain
elig
criteria
trial
identifi
search
extract
inform
regard
studi
method
assess
data
includ
analys
patient
age
sex
investig
treatment
paracetamol
consumpt
inabl
attend
school
due
atp
ab
studi
meet
elig
criteria
includ
analys
without
restrict
patient
inform
extract
raw
data
identifi
trial
made
avail
studi
sponsor
sampl
characterist
analys
use
applic
descript
summari
measur
cumul
paracetamol
consumpt
amount
mg
metaanalysi
perform
across
elig
trial
comput
differ
mean
valu
treatment
group
associ
confid
interv
ci
origin
scale
sinc
elig
trial
use
differ
prescript
paracetamol
dose
see
detail
size
effect
could
exclud
use
hedg
g
standardis
effect
size
measur
perform
metaanalysi
moreov
percentag
children
adolesc
unabl
attend
school
end
schedul
treatment
period
enter
metaanalysi
base
risk
ratio
ci
heterogen
trial
assess
use
test
heterogen
statist
pool
metaanalysi
estim
obtain
use
random
effect
model
throughout
review
manag
version
softwar
use
metaanalys
specifi
pvalu
twosid
metaanalys
treatment
differ
consid
descript
signific
ci
point
estim
includ
valu
differ
valu
risk
ratio
correspond
descript
pvalu
p
analys
perform
base
full
analysi
set
studi
particip
primari
data
set
analysi
efficaci
origin
trial
patient
termin
studi
particip
prematur
cumul
paracetamol
intak
calcul
time
period
start
randomis
treatment
earli
withdraw
analysi
abil
attend
school
base
last
avail
inform
search
identifi
total
uniqu
public
five
review
articl
addit
origin
public
meet
select
criteria
could
infer
five
present
result
clinic
trial
ep
indic
interest
includ
children
year
age
one
public
report
pilot
studi
particip
children
particip
year
age
author
report
paracetamol
consumpt
remain
public
met
elig
criteria
includ
metaanalysi
fig
elig
studi
doubleblind
randomis
placebocontrol
trial
publish
peerreview
journal
randomis
sequenc
gener
independ
statistician
use
valid
softwar
studi
investig
medicin
product
dispens
sequenti
number
contain
ident
appear
particip
subject
receiv
studi
medic
correspond
lowest
yet
unassign
randomis
number
avail
applic
centr
studi
sponsor
dr
willmar
schwabe
gmbh
co
kg
manufactur
ep
also
provid
origin
patient
data
metaanalys
main
characterist
trial
shown
tabl
three
studi
b
c
investig
efficaci
safeti
ep
atp
accord
similar
protocol
includ
girl
boy
year
age
present
sign
symptom
atp
persist
h
neg
rapid
antigendetect
test
streptococci
requir
order
exclud
children
ga
moreov
minimum
total
score
point
tonsillopharyng
symptom
scale
tss
symptom
assess
dysphagia
sore
throat
saliv
red
coat
left
coat
right
fever
total
score
rang
point
trial
point
tss
symptom
assess
dysphagia
sore
throat
saliv
red
fever
total
score
rang
point
trial
b
c
appli
assur
suffici
symptom
sever
schedul
treatment
period
trial
atp
day
ab
trial
e
f
perform
accord
protocol
similar
target
popul
studi
procedur
schedul
assess
identifi
investig
male
femal
children
adolesc
age
subset
children
year
age
includ
metaanalysi
studi
elig
particip
present
sign
symptom
ab
persist
h
prior
inclus
inclus
protocol
also
requir
total
score
point
bronchiti
sever
scale
bss
symptom
assess
cough
sputum
product
rale
auscult
chest
pain
cough
dyspnea
total
score
rang
point
like
trial
atp
particip
studi
f
receiv
ep
solut
trial
e
dose
find
studi
whose
particip
randomis
receiv
tablet
mgday
ep
placebo
present
metaanalysi
children
receiv
market
dose
mgday
placebo
consid
trial
ab
treatment
durat
day
total
number
children
analys
ep
atp
ab
atp
ab
placebo
protocol
elig
studi
allow
paracetamol
suppositori
tablet
support
medic
case
fever
trial
atp
paracetamol
allow
day
start
randomis
treatment
maximum
daili
dose
mg
protocol
studi
f
permit
mg
suppositori
per
day
children
year
age
older
children
mg
tablet
permit
studi
concern
studi
f
mg
suppositori
allow
children
year
mg
tablet
older
children
studi
e
mg
tablet
per
day
allow
children
age
administ
dose
document
concomit
medic
potenti
impact
studi
outcom
andor
cours
atp
ab
e
g
antibiot
treatment
forbidden
tabl
show
basic
demograph
data
studi
particip
patient
age
compar
ep
placebo
also
atp
ab
coincident
children
randomis
ep
femal
compar
male
wherea
children
receiv
placebo
male
atp
ab
trial
atp
perform
accord
adapt
groupsequenti
design
wherea
studi
ab
use
design
one
adapt
interim
analysi
measur
implement
control
bia
individu
studi
level
includ
recruit
consecut
elig
children
whose
legal
repres
provid
inform
consent
blind
investig
treatment
includ
blind
outcom
assess
well
randomis
assign
ep
placebo
contact
manufactur
ep
assur
randomis
placebocontrol
studi
investig
administr
product
children
atp
ab
identifi
public
bia
rule
includ
analys
studi
perform
indic
popul
interest
sinc
studi
report
data
predefin
outcom
measur
interest
analys
risk
withinstudi
select
report
studi
c
investig
efficaci
ep
symptomat
treatment
atp
main
efficaci
assess
base
tss
total
score
chang
studi
primari
outcom
measur
respond
rate
respons
defin
tss
total
score
point
day
randomis
treatment
children
ep
group
respond
compar
children
receiv
placebo
p
fisher
exact
test
primari
outcom
measur
treatment
efficaci
studi
b
c
chang
tss
total
score
baselin
treatment
day
studi
b
tss
total
score
decreas
mean
sd
point
observ
ep
placebo
respect
ci
mean
valu
differ
point
studi
c
children
treat
ep
show
tss
total
score
decreas
point
compar
point
placebo
group
ci
mean
valu
differ
point
efficaci
ep
symptomat
treatment
ab
investig
studi
f
predefin
primari
efficaci
outcom
measur
trial
bss
total
score
chang
baselin
day
bss
total
score
reduc
point
ep
point
placebo
trial
p
treatment
main
effect
analysi
covari
model
also
includ
main
effect
centr
bss
baselin
valu
covari
appli
studi
f
point
ep
mgday
point
placebo
trial
e
p
point
ep
point
placebo
trial
f
p
ab
result
appli
primari
analys
accord
studi
protocol
includ
patient
entir
age
rang
elig
trial
particip
e
year
studi
f
year
studi
e
separ
analys
age
rang
year
consid
metaanalysi
perform
figur
show
main
result
metaanalysi
cumul
paracetamol
use
studi
particip
averag
cumul
paracetamol
dose
administ
treatment
group
ab
gener
somewhat
lower
atp
studi
includ
analysi
show
lower
averag
cumul
paracetamol
dose
ep
group
show
lower
dose
placebo
group
studi
level
treatment
group
differ
rang
mg
decreas
mg
increas
averag
paracetamol
dose
ep
group
compar
placebo
weigh
mean
differ
mg
across
studi
favour
ep
metaanalysi
show
averag
cumul
paracetamol
dose
significantli
lower
ep
group
compar
placebo
hedg
g
ci
p
signific
differ
favour
ep
also
observ
studi
b
c
p
diagnost
test
perform
context
metaanalysi
indic
moder
heterogen
treatment
effect
observ
analys
trial
test
p
mainli
attribut
discrep
result
studi
f
trial
number
children
unabl
attend
school
treatment
end
identifi
event
significantli
higher
placebo
group
compar
ep
studi
includ
fig
pool
data
set
observ
event
rate
children
children
ep
placebo
respect
correspond
metaanalysi
risk
ratio
ci
p
favour
ep
metaanalysi
valu
test
p
indic
substanti
heterogen
trial
result
heterogen
howev
caus
magnitud
direct
treatment
effect
sinc
advantag
ep
placebo
observ
includ
trial
studi
show
signific
effect
even
consid
individu
acut
rti
ab
atp
usual
associ
febril
temperatur
rang
requir
antipyret
treatment
contrari
medic
unnecessari
antipyresi
may
interfer
organ
adapt
respons
viral
infect
may
thu
even
prolong
ill
although
prolong
persist
fever
therefor
avoid
consequ
current
guidelin
recommend
use
antipyret
agent
sole
aim
reduc
bodi
temperatur
children
fever
although
paracetamol
wide
use
antipyret
medic
children
long
recogn
safe
efficaci
use
recommend
dose
rang
nevertheless
also
associ
advers
effect
may
potenti
seriou
although
rare
probabl
seriou
complic
paediatr
set
hepatotox
caus
accident
overdos
medic
error
involv
paracetamol
surpris
sinc
drug
wide
use
children
avail
fig
averag
cumul
paracetamol
use
mg
standardis
effect
size
hedg
g
mani
differ
formul
parent
may
sometim
even
awar
administ
paracetamol
moreov
convinc
evid
paracetamol
use
infant
even
expect
women
may
increas
risk
asthma
rhinoconjunct
eczema
children
although
recent
metaanalysi
show
childhood
asthma
may
also
relat
respiratori
infect
infanc
rather
paracetamol
administ
treat
antipyret
drug
paracetamol
gener
found
improv
comfort
ill
child
thu
also
reduc
strain
parent
health
care
profession
may
reason
drug
wide
use
even
though
antipyresi
shown
unhelp
trivial
viral
infect
inde
improv
overal
wellb
ill
child
primari
object
support
therapi
sinc
commonli
use
antipyret
drug
includ
paracetamol
exert
benefici
influenc
trivial
infect
mainli
analges
rather
antipyret
effect
may
prefer
revert
treatment
provid
symptom
control
improv
child
overal
comfort
acceler
recoveri
without
caus
unneed
antipyresi
analys
symptom
scale
predefin
primari
outcom
measur
trial
includ
metaanalysi
confirm
ep
efficaci
reduc
symptom
burden
acceler
recoveri
children
suffer
ab
atp
metaanalysi
add
exist
evid
demonstr
ep
also
reduc
use
paracetamol
enabl
atpand
abaffect
children
return
school
earlier
thu
effect
shorten
cours
diseas
protocol
studi
includ
metaanalysi
allow
paracetamol
comed
case
fever
although
studi
explicitli
assess
whether
drug
administ
analgesia
antipyresi
permiss
use
paracetamol
associ
child
temperatur
level
may
thu
reason
assum
decis
parent
administ
drug
primarili
motiv
reduct
fever
sinc
ep
known
direct
antipyret
effect
fact
cumul
paracetamol
dose
ep
group
systemat
lower
placebo
group
may
indic
children
treat
herbal
product
less
febril
result
antipyret
treatment
favour
cours
infect
also
consist
observ
children
expos
ep
recov
rti
associ
symptom
rapidli
betweenstudi
heterogen
observ
metaanalys
mainli
attribut
differ
magnitud
effect
favour
ep
rather
direct
effect
paracetamol
consumpt
trial
metaanalysi
show
lower
antipyret
use
ep
group
compar
placebo
descript
signific
advantag
ep
trial
inabl
attend
school
includ
studi
favour
ep
show
descript
signific
advantag
herbal
product
metaanalys
also
indic
howev
effect
size
ep
placebo
somewhat
pronounc
studi
perform
atp
ab
also
contribut
observ
heterogen
methodolog
weak
studi
observ
use
paracetamol
could
intraindividu
correl
actual
bodi
temperatur
sinc
temperatur
measur
report
systemat
instead
reli
instruct
given
parent
administ
paracetamol
case
bodi
temperatur
higher
anoth
weak
lie
compar
small
number
subject
avail
metaanalysi
notabl
ab
subset
children
year
age
elig
fig
number
children
unabl
go
school
day
acut
tonsillopharyng
day
acut
bronchiti
start
treatment
analysi
noteworthi
howev
sampl
size
studi
plan
accord
statist
consider
prove
suffici
demonstr
superior
ep
placebo
predefin
primari
outcom
measur
moreov
particularli
vulner
patient
popul
like
children
hardli
justifi
ethic
perspect
includ
subject
placebocontrol
trial
minimum
number
requir
provid
accept
statist
power
achiev
primari
studi
object
conclus
randomis
control
trial
confirm
ep
reduc
sever
durat
diseas
associ
symptom
children
nonga
atp
ab
result
support
add
find
show
children
treat
ep
requir
less
paracetamol
comed
abl
return
school
earlier
consid
observ
patientrelev
benefit
sinc
ep
amelior
unpleas
effect
febril
respons
achiev
symptomat
improv
acceler
restaur
normal
function
without
potenti
counterproduct
antipyresi
also
reduc
patient
risk
avoid
potenti
harm
side
effect
paracetamol
avail
data
materi
due
ethic
reason
term
data
protect
law
raw
data
share
request
extent
permit
law
trial
data
requir
valid
purpos
alreadi
disclos
result
report
correspond
databas
relev
data
within
paper
author
contribut
gs
involv
interpret
data
revis
paper
critic
intellectu
content
final
approv
version
publish
jb
involv
concept
design
work
analysi
interpret
data
draft
paper
final
approv
version
publish
az
involv
concept
design
work
analysi
interpret
data
draft
paper
final
approv
version
publish
wl
involv
interpret
data
revis
paper
critic
intellectu
content
final
approv
version
publish
wk
involv
interpret
data
revis
paper
critic
intellectu
content
final
approv
version
publish
author
agre
account
aspect
work
author
read
approv
final
manuscript
studi
includ
metaanalysi
review
approv
compet
independ
ethic
committe
parent
particip
children
provid
written
inform
consent
detail
found
origin
public
